| Expression of oestrogen and progesterone receptors by mast cells alone, but not lymphocytes, macrophages or other immune cells in human upper airways XJ Zhao, G McKerr, Z Dong, CA Higgins, J Carson, ZQ Yang, ... Thorax 56 (3), 205-211, 2001 | 163 | 2001 |
| Differential affinity of FLIP and procaspase 8 for FADD’s DED binding surfaces regulates DISC assembly J Majkut, M Sgobba, C Holohan, N Crawford, AE Logan, E Kerr, ... Nature communications 5 (1), 1-12, 2014 | 102 | 2014 |
| Mechanistic and anti-proliferative studies of two novel, biologically active bis-benzimidazoles A Seaton, C Higgins, J Mann, A Baron, C Bailly, S Neidle, H Van den Berg European Journal of Cancer 39 (17), 2548-2555, 2003 | 58 | 2003 |
| A revised model of TRAIL‐R2 DISC assembly explains how FLIP (L) can inhibit or promote apoptosis LM Humphreys, JP Fox, CA Higgins, J Majkut, T Sessler, K McLaughlin, ... EMBO reports 21 (3), e49254, 2020 | 52 | 2020 |
| TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities. ZC D'Costa, C Higgins, CW Ong, GW Irwin, D Boyle, DG McArt, ... Oncotarget 5 (6), 1609, 2014 | 48 | 2014 |
| Growth inhibitory activity of extracted material and isolated compounds from the fruits of Kigelia pinnata CA Higgins, T Bell, Z Delbederi, S Feutren-Burton, B McClean, C O'Dowd, ... Planta medica 76 (16), 1840-1846, 2010 | 42 | 2010 |
| FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung CancerFLIP-Mediated Radioresistance in NSCLC KA McLaughlin, Z Nemeth, CA Bradley, L Humphreys, I Stasik, C Fenning, ... Molecular cancer therapeutics 15 (10), 2432-2441, 2016 | 31 | 2016 |
| Synthesis and in vitro and in vivo evaluation of a series of dihydroisocoumarin derivatives conjugated with fatty acids, alcohols, and amines as potential anticancer agents CA Higgins, Z Delbederi, K McGarel, T Mills, O McGrath, S Feutren-Burton, ... Bioconjugate chemistry 20 (9), 1737-1751, 2009 | 25 | 2009 |
| Development of a potent and selective cell penetrant Legumain inhibitor KA Ness, SL Eddie, CA Higgins, A Templeman, Z D’Costa, KKD Gaddale, ... Bioorganic & Medicinal Chemistry Letters 25 (23), 5642-5645, 2015 | 21 | 2015 |
| Therapeutics targeting the core apoptotic machinery C Hamilton, JP Fox, DB Longley, CA Higgins Cancers 13 (11), 2618, 2021 | 15 | 2021 |
| P3 SAR exploration of biphenyl carbamate based Legumain inhibitors C Higgins, S Bouazzaoui, K Gaddale, Z D’Costa, A Templeman, ... Bioorganic & Medicinal Chemistry Letters 24 (11), 2521-2524, 2014 | 13 | 2014 |
| Macrophages and apoptotic cells in human colorectal tumours CA Higgins, WJ Hatton, G McKerr, D Harvey, J Carson, BM Hannigan Biologicals 24 (4), 329-332, 1996 | 10 | 1996 |
| Development of first-in-class small molecule inhibitors of FLIP which activate caspase-8, the nodal regulator of apoptosis, necroptosis and pyroptosis DB Longley, C Higgins, J Fox, JZ Roberts, R Boffey, S Williams, T Perrior, ... Cancer Research 80 (16_Supplement), 5220-5220, 2020 | 5 | 2020 |
| Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP CA Higgins, J Fox, J Majkut, GE Fiedler, J Roberts, L Humphreys, ... Cancer Research 79 (13_Supplement), 382-382, 2019 | 2 | 2019 |
| Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP for treatment of NSCLC and CRC CA Higgins, J Majkut, L Humphreys, J Fox, M Espona-Fiedler, A Malik, ... European Journal of Cancer 1 (69), S6, 2016 | 2 | 2016 |
| Regulation of FLIP (L) and TRAIL-R2 signalling by the SCFSkp2 Ubiquitin Ligase Complex JZ Roberts, C Holohan, T Sessler, J Fox, C Higgins, G Espona-Fiedler, ... bioRxiv, 723718, 2019 | 1 | 2019 |
| Correction: Hamilton et al. Therapeutics Targeting the Core Apoptotic Machinery. Cancers 2021, 13, 2618 C Hamilton, JP Fox, DB Longley, CA Higgins Cancers 14 (6), 1441, 2022 | | 2022 |
| Therapeutics Targeting the Core Apoptotic Machinery (vol 13, 2618, 2021) C Hamilton, JP Fox, DB Longley, CA Higgins CANCERS 14 (6), 2022 | | 2022 |
| Correction: Hamilton et al. Therapeutics Targeting the Core Apoptotic Machinery. Cancers 2021, 13, 2618. Cancers 2022, 14, 1441 C Hamilton, JP Fox, DB Longley, CA Higgins s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | | 2022 |
| Therapeutics Targeting the Core Apoptotic Machinery. Cancers 2021, 13, 2618 C Hamilton, JP Fox, DB Longley, CA Higgins s Note: MDPI stays neu-tral with regard to jurisdictional claims in …, 2021 | | 2021 |
